IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 15, 2024

Primary Completion Date

June 15, 2025

Study Completion Date

June 15, 2026

Conditions
Refractory OsteosarcomaRecurrent Osteosarcoma
Interventions
BIOLOGICAL

IM83 CAR-T Cells

IM83 CAR-T Cells, 5×10\^8 cells, 1×10\^9 cells, and 2×10\^9 cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D- 3), determined by tumor burden at baseline. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline.

Trial Locations (1)

519041

Guangdong Provincial People's Hospital, Guangdong

All Listed Sponsors
collaborator

Guangdong Provincial People's Hospital

OTHER

lead

Beijing Immunochina Medical Science & Technology Co., Ltd.

INDUSTRY

NCT06412458 - IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma | Biotech Hunter | Biotech Hunter